Gentamicin reduces serum ACE activity in patients with normal kidney function.
OBJECTIVE
We evaluated serum angiotensin-converting enzyme (ACE) as an indicator of gentamicin toxicity and compared it with N-acetyl-beta-D-glucosaminidase (NAG) and creatinine.


METHODS
20 bone fracture in-patients receiving gentamicin 80 mg TDS for 3 days. Subjects had normal kidney function and had no history or sign of hypertension. Serum and urine samples were collected before and 3 days after drug administration. Samples analyzed for ACE, NAG, BUN, creatinine, sodium, and potassium.


RESULTS
Our results showed that urine NAG activity increased significantly at the 3rd day. Serum creatinine level and glomerular filtration rate (GFR) while still at a normal range showed slight but significant changes at this time. This may indicate some renal damage. Serum ACE activity decreased significantly at the 3rd day.


CONCLUSIONS
These results indicate serum ACE can be used as a good indicator of renal damage in patients receiving gentamicin.
Ziai
Seyed Ali
SA
Department of Pharmacology, Institute of Medicinal Plants and Natural Products, ACECR, Tehran, Iran.
Mooraki
Ahmed
A
Mahmoudian
Massoud
M
D000118:Acetylglucosaminidase / Q000097:blood / Q000652:urine; D000328:Adult; D015415:Biomarkers / Q000097:blood*; D003404:Creatinine / Q000097:blood / Q000652:urine; D050723:Fractures, Bone / Q000188:drug therapy; D005839:Gentamicins / Q000633:toxicity*; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D007703:Peptidyl-Dipeptidase A / Q000097:blood*
D015415:Biomarkers; D005839:Gentamicins; D003404:Creatinine; D000118:Acetylglucosaminidase; D007703:Peptidyl-Dipeptidase A